Weekly channel feed

Pre­view­ing bio­phar­ma trends ahead of #BIO22; Look­ing back at #AS­CO22; Smooth flight for blue­bird?; and more

3 years ago

Lat­est news out of #AS­CO22; GSK, Bris­tol My­ers get M&A go­ing in vac­cines, on­col­o­gy; Roche's pact spot­lights new can­cer tar­get; and more

3 years ago

Bio­mark­er 'roadmap­s' and the fu­ture of can­cer R&D; Cur­tain rais­es on #AS­CO22; Pfiz­er, No­var­tis tack­le drug ac­cess; and more

3 years ago

Amid mon­key­pox fears, biotechs spring to ac­tion; Mod­er­na’s CFO trou­ble; Cuts, cuts every­where; Craft­ing the right pro­teins; and more

3 years ago

Pfiz­er's $11.6B wa­ger; TIG­IT im­plo­sion; An un­usu­al phar­ma-biotech pact; In­side a16z's vi­sion to re­shape biotech; and more

3 years ago

Bio­gen's shake­up from the top; How to build a biotech to­day; David Saba­ti­ni backs out of NYU; and more

4 years ago

Your guide to phar­ma Q1 num­bers; Un­pack­ing top 15 R&D gi­ants; Se­cret PhI­II fail­ures; 'Weirdo sci­ence' and meta­science; and more

4 years ago

End­points 20 un­der 40; Ver­dict on PI3K; Re­gen­eron goes dis­count shop­ping; $1.85B deal im­plodes; and more

4 years ago

Zoom­ing in on a biotech lay­off; $1.9B buy­out to fill M&A void; Covid win­ners ap­point new fi­nance chiefs; and more

4 years ago

Lat­est news on ‘dev­as­tat­ing’ Ab­b­Vie drug dis­con­tin­u­a­tion; Bio­gen's worst case sce­nario; Fi­nal­ly, some M&A; and more

4 years ago

A Penn spin­out goes dark; Thumbs down on ALS drug; TIG­IT runs in­to PhI­II flop; Sanofi's got big plans; and more

4 years ago

ALS drug sets the stage for fresh FDA de­bate; Im­plo­sions every­where you look; Big names turn up at biotechs; and more

4 years ago

Lat­est news on first-ever Lag-3 OK; Aduhelm sup­port, crit­i­cism both crescen­do; Phar­ma gets firm about Rus­sia; Set­backs mar top R&D prospects; and more

4 years ago

Re­vamp com­ing at Gilead; Lat­est from in Ukraine, Rus­sia; Bio­gen’s hang­ing bud­get ax; No­var­tis places gene ther­a­py bet; and more

4 years ago

The Pfiz­er pa­pers; Bio­gen lay­offs be­gin; Ab­b­Vie inks a buy­out; GSK makes Slaoui pay; and more

4 years ago

Lat­est news on J&J's ma­jor court win; Ukraine's place in biotech; Man­ag­ing ex­pec­ta­tions for AI; Lil­ly ups its RNA game; and more

4 years ago

In­side PBM­s' tac­tics to tilt the mar­ket; Is the KRAS race still on? CAR-T safe­ty scares trig­ger halts; and more

4 years ago

Lat­est news on Covid vac­cine de­lay for kids; Door slammed shut for Chi­na-on­ly da­ta; Er­ic Lan­der is out; Look­ing back at the boom; and more

4 years ago

R&D heads play phar­ma mu­si­cal chairs; Shat­tered block­buster dreams; Death of Aduhelm?; and more

4 years ago

'Thor­ough­ly f*****d' for cy­ber­at­tacks?; Bad week for drug de­vel­op­ers; The next big I/O break­through?; Bio­gen does a deal; and more

4 years ago

What lured Hal Bar­ron away?; Top FDA minds on ac­cel­er­at­ed ap­proval re­forms; ‘Dead wrong’ Aduhelm ad blitz; and more

4 years ago

Lat­est news on Pfiz­er's $3B+ JAK1 win; Pacts over M&A at #JPM22; 2021 by the num­bers; Bio­gen's Aduhelm reck­on­ing; The sto­ry of sotro­vimab; and more

4 years ago

Three AI deals kick off #JPM22 week­end; Can Sil­i­con Val­ley change how sci­ence gets fund­ed?; Spe­cial re­port: 2021 new drug ap­provals; and more

4 years ago

It’s be­gin­ning to look a lot like M&A sea­son; Aduhelm runs in­to more re­sis­tance; Eli Lil­ly, Bris­tol My­ers get in ear­ly on can­cer ef­forts; and more

4 years ago
First page Previous page 456789 Next page Last page
A service from the Financial Times